Market capitalization | $33.94m |
Enterprise Value | $32.69m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 544.83 |
P/S ratio (TTM) P/S ratio | 565.67 |
P/B ratio (TTM) P/B ratio | 4.83 |
Revenue (TTM) Revenue | $60.00k |
EBIT (operating result TTM) EBIT | $-11.19m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
1 Analyst has issued a forecast Coeptis Therapeutics:
1 Analyst has issued a forecast Coeptis Therapeutics:
Mar '25 |
+/-
%
|
||
Revenue | 0.06 0.06 |
-
|
|
Gross Profit | -2.09 -2.09 |
109%
109%
|
|
EBITDA | -10 -10 |
40%
40%
|
EBIT (Operating Income) EBIT | -11 -11 |
37%
37%
|
Net Profit | -11 -11 |
33%
33%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company. It develops innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.
Head office | United States |
CEO | David Mehalick |
Employees | 7 |
Founded | 2017 |
Website | www.coeptistx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.